43 results about "Cell wall synthesis" patented technology

The invention is based on the discovery of a new class of heterocyclic compounds having, for example, antibacterial properties. The D-Ala-D-Ala ligase enzyme is a critical pathway enzyme in the bacterial cell-wall synthesis. The compounds can bind to and inhibit the enzyme D-Ala-D-Ala ligase. The new compounds' activity combined with their ability to cross bacterial cell membranes makes them suitable for use as antibacterial drugs or other antibacterial applications.

The invention discloses an attapulgite material with an anti-bacterial function and a preparation method thereof. The preparation method of the attapulgite material comprises the following main steps of: packaging certain materials containing amine groups onto the surface of the attapulgite by virtue of a functional water agent preparation process, a pelletizing process, a drying process and the like; enabling the attapulgite to have the special performances of the modified material while not damaging the structure of the attapulgite. The modified material can be used for absorbing bacteria with negative charges, so that negative charges on bacterial cell walls and cell membranes are not uniformly distributed, the synthesis of the cell walls is interfered, the cell wall synthesis and solubility equilibrium under the natural condition is broken through, and the bacteria are dissolved and died, and therefore, the anti-bacterial and bacteriostatic performances are achieved.

The invention discloses a method for improving apparent catalytic activity of glutamic acid decarboxylase recombinant engineering bacteria. The method comprises the steps of inoculating the glutamic acid decarboxylase recombinant engineering bacteria into a culture medium for shake cultivation so as to obtain a seed solution; inoculating the seed solution into the culture medium for shake cultivation, adding an inducer for induction cultivation when OD600 is 0.6-0.8 hour, and simultaneously adding a cell wall synthesis inhibitor or surfactant into the culture medium so as to interfere in synthesis of recombinant bacteria cell walls or (and) cell membranes to achieve the purposes of enhancing the permeability of the bacteria and improving the apparent catalytic activity of the bacteria; and after induction cultivation, collecting the bacteria so as to obtain the glutamic acid decarboxylase recombinant engineering bacteria with the apparent catalytic activity improved. The method for improving apparent catalytic activity of glutamic acid decarboxylase recombinant engineering bacteria is free from multiple processing steps for permeability treatment after cultivation of conventional bacteria and is simple, convenient and efficient, and low in cost.

The invention relates to a related gene for regulating and controlling wood development and application thereof, and particularly provides a novel PtMAN6 polypeptide or a coding sequence thereof. An amino acid sequence of the PtMAN6 polypeptide is shown as SEQ ID NO.:2, and the coding sequence is shown as SEQ ID NO.:1.The invention further provides a PtMAN6 gene and application of protein coded by the PtMAN6 gene. The PtMAN6 gene can reduce synthesis of xylem secondary cell walls and / or reduce accumulation of crystalline fiber biomass; mannan hydrolase of mannan hemicellulose can be enriched and degraded in plants by excessively expressing the PtMAN6; meanwhile, due to the regulating and controlling effect of the PtMAN6, the lignin content in transgenic plants is decreased, crystalline cellulose is decreased, and therefore the cost in lignocelluloses ethanol producing and paper making industry is greatly reduced; a promoter of the PtMAN6 gene has the specific duct cell positioning function and can precisely regulate and control expression of the gene in xylem duct cells.

Compositions and methods are provided for the use of SOS pathway targeted agents in antimicrobial formulations. The innate sensitivity of bacteria to antibiotics is increased by disrupting a mechanism that normally activates the bacterial SOS response or by inhibiting steps in the SOS response pathway itself. SOS response induction can result from exposure of bacteria to certain antibiotics, including β-lactam antibiotics and other agents that affect cell wall synthesis. By transiently delaying bacterial cell division, SOS response induction interferes with bacterial killing by ordinarily lethal concentrations of these drugs A pharmaceutical composition comprising an SOS targeted agent is administered to a patient suffering from a microbial infection, in combination with an antibiotic that induces an SOS response. The identification of the SOS pathway as a target for modulating antibiotic action provides a basis for further therapeutic development, through screening assays designed to detect molecules or genes that act on these pathways.

The invention relates to a method used for increasing 2,3-butylene glycol yield. The method is mainly used for solving a problem of existing technology that yield of 2,3-butylene glycol is relatively low. According to the method, bacteria are subjected to high sugar resistance domestication firstly; the domesticated bacteria are used for fermentation culturing, and an antibiotic is added in fermentation culturing processes, wherein the antibiotic is at least one selected from penicillin, cephalosporin, bacillus, D-cycloserine, and the like which are capable of inhibiting cell wall synthesis, and polymyxin B, nystatin, amphotericin, or valinomycin which are capable of influencing cytomembrane functions, and adding concentration of the antibiotic ranges from 0.0001 to 5g / L. The method is capable of increasing 2,3-butylene glycol yield, and can be used for production of 2,3-butylene glycol.

Methods are provided for increasing plant growth rate, biomass and tolerance to stress by genetically engineering plants to contain and express a gene of the ascorbic acid synthesis-cell wall synthesis network (e.g. GlcUA reductase, GLOase or MIOX). Transgenic plants that are genetically engineered in such a manner are also provided.

The invention relates to the use of a pharmaceutical composition for the local treatment or prevention of a tissue infection at an infection site, the pharmaceutical composition comprising at least two different antibiotics of group A or pharmaceutically acceptable derivatives thereof, or an antibiotic of group A and at least one antibiotic of group B or pharmaceutically acceptable derivatives thereof. Group A comprises primarily intracellular active antibiotics working as inhibitor of bacterial RNA polymerase; as inhibitor of gyrase; or as inhibitor of bacterial protein synthesis. Group B comprises primarily extracellular active antibiotics working as inhibitor of bacterial cell wall synthesis; or inhibitor of bacterial protein synthesis; or by direct destabilization or rupture of the bacterial cell wall.The invention further relates to a pharmaceutical composition for treatment of extracellular and / or intracellular microbial infected cells and / or for the prevention of microbial cell infections comprising at least one antibiotic acting as an inhibitor of bacterial RNA polymerase and / or at least one antibiotic affecting the bacterial cell wall or its synthesis, and a substrate carrying a pharmaceutical composition.The invention also relates to the use of a combination of at least one antibiotic acting as an inhibitor of bacterial RNA polymerase and at least one antibiotic affecting the bacterial cell wall or its synthesis as anti-adhesive against microorganisms on surfaces.

The invention discloses a construction method for double-gene mutation escherichia coli used for secretory expression of recombinant protein. According to the invention, pre-designed primers for the double-knockout-genes of cell membrane protein and cell wall synthetase gene are used for a PCR reaction so as to obtain gene targeting fragments of the double-knockout-gene, wherein two ends of each gene targeting fragment are 10 to 250 bp homologous sequences of a specific target gene and the middle part of each gene targeting fragment is a resistance labeled sequence; the fragments are respectively integrated into chromosomes of the host escherichia coli through electrotransformation so as to obtain a secretory double-gene mutation escherichia coli strain. The method provided by the invention increases the expression of recombinant exogenous proteins, reduces intracellular degradation of target proteins, decreases intracellular accumulation of the recombinant exogenous proteins and eradicates formation of inclusion bodies; the method discards a breaking process for cell walls, reduces pyrogen and simplifies separation and purification; thus, the purposes of reducing production cost and improving protein expression and product quality are achieved.

The invention relates to the technical field of plant tissue culture, in particular to a method for culturing phyllostachys edulis protoplast and inducing cell wall regeneration and application of the method. The protoplast derived from the phyllostachys edulis embryogenic callus is cultured and induced to regenerate the complete cell wall, the regeneration effect is excellent, the success rate is high, and meanwhile, the regeneration result has high repeatability. In addition, the protoplast and cell wall regeneration process can be monitored by the method; a feasible model is provided for researching cell wall synthesis and regulation control mechanisms of phyllostachys edulis and other species, material improvement, biomass energy and other fields; theoretical guidance is provided for improving the quality and yield of bamboo cell walls; and the method has profound influence and long-term significance on the construction and development of the bamboo industry.

The present invention relates to a composition comprising at least one biological control agent. Furthermore, the present invention relates to the use of this composition as well as a method for reducing overall damage of plants and plant parts.

A method of rapidly evaluating the susceptibility of a strain of bacteria to a cell wall synthesis inhibiting antibiotic based on an assessment of cell enlargement in response to doses of the cell wall synthesis inhibiting antibiotic which are correlated to breakpoints of bacterial susceptibility.

The invention discloses a plant gene promoter and its application. The base sequence of the promoter is shown in SEQ ID NO:1. Tobacco transgenic experiments proved that pGhGlcat1 can endow high-level expression of GUS reporter gene in epidermal trichomes, apical meristem region, and stamens and pistils of plant floral organs, indicating that GhGlcat1 plays a role in cotton fiber primary cell wall synthesis, cell elongation, floral organ development and stress The functional study of pGhGlcat1 provides clues for revealing the expression regulation mechanism of GhGlcat1. In addition, pGhGlcat1 can also be used in the genetic engineering improvement of plant quality and resistance.

A C-terminus modification to a binding pocket-modified vancomycin introduces a quaternary ammonium salt that provides a binding pocket-modified vancomycin analog with a second mechanism of action that is independent of D-Ala-D-Ala / D-Ala-D-Lac binding. The modification disrupts cell wall integrity and induces cell wall permeability complementary to the glycopeptide inhibition of cell wall synthesis, and provides synergistic improvements in antimicrobial potency (200-fold) against vancomycin-resistant bacteria. Combining the C-terminus and binding pocket modifications with an orthogonal (4-chlorobiphenyl) methyl addition to the vancomycin disaccharide provides even more potent antimicrobial agents whose activity can be attributed to three independent and synergistic mechanisms of action, only one of which requires D-Ala-D-Ala / D-Ala-D-Lac binding. The resulting modified vancomycins display little propensity for acquired resistance through serial exposure of vancomycin-resistant Enterococci and their durability against such challenges as well as their antimicrobial potency follow predicable trends. Methods of treatment with and compositions containing the modified vancomycins are disclosed.

A method of antibiotic susceptibility testing is disclosed, and includes the following steps: (A) providing a sample to be tested wherein the sample contains a microbe; (B) adding an antibiotic into the sample, wherein the antibiotic serves to inhibit cell wall synthesis; (C) checking the sample by dielectrophoresis and observing a shape change of the microbe; and (D) determining whether the microbe is susceptible to the antibiotic according to the shape change thereof. The present invention also discloses a method for determining a minimum inhibitory concentration of the antibiotic.